IQV vs NIQ
IQV: IQVIA is a global leader in clinical research and healthcare data analytics that powers the development and commercialization of life-saving medical treatments. NIQ: A leading global consumer intelligence firm providing an AI-powered, omnichannel view of shopping behavior to help brands and retailers drive performance and innovation.
Side-by-side fundamentals
| Metric | IQV | NIQ | Edge |
|---|---|---|---|
| Price as of 2026-10-09 close | $259.88 | $18.09 | |
| Market cap | $43.4B | $5.3B | |
| P/E as of 2026-10-09 | 32.22 | n/a | |
| PEG as of 2026-10-09, 3-year EPS CAGR to FY2025 | 2.91 | n/a | |
| Net margin FY2025, SEC XBRL | +8.3% | -8.4% | IQV higher |
| Operating margin FY2025, SEC XBRL | +13.4% | +2.0% | IQV higher |
| ROE FY2025, SEC XBRL | +20.5% | -28.8% | IQV higher |
| ROA FY2025, SEC XBRL | +4.5% | -5.2% | IQV higher |
| Debt / equity as of 2026-09-02 | 2.59 | 3.89 | IQV lower |
| Revenue growth (YoY) as of 2026-09-02 | +8.2% | +44.0% | NIQ higher |
| Revenue CAGR (3y) SEC XBRL | +4.2% | +12.1% | NIQ higher |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-09-02 | 0.97 | 0.71 | |
| 1-year return as of 2026-10-09 close | +28.0% | +25.8% | IQV higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.